Anna M Milan

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/2610964/publications.pdf

Version: 2024-02-01

55 papers	1,349 citations	361045 20 h-index	377514 34 g-index
57 all docs	57 docs citations	57 times ranked	1003 citing authors

#	Article	IF	Citations
1	Metabolomic studies in the inborn error of metabolism alkaptonuria reveal new biotransformations in tyrosine metabolism. Genes and Diseases, 2022, 9, 1129-1142.	1.5	13
2	Comparing nitisinone 2 mg and 10 mg in the treatment of alkaptonuriaâ€"An approach using statistical modelling. JIMD Reports, 2022, 63, 80-92.	0.7	7
3	Effects of a proteinâ€restricted diet on body weight and serum tyrosine concentrations in patients with alkaptonuria. JIMD Reports, 2022, 63, 41-49.	0.7	4
4	Vitamin D, vitamin Dâ€"binding protein, free vitamin D and COVID-19 mortality in hospitalized patients. American Journal of Clinical Nutrition, 2022, 115, 1367-1377.	2.2	12
5	Characterization of changes in the tyrosine pathway by 24-h profiling during nitisinone treatment in alkaptonuria. Molecular Genetics and Metabolism Reports, 2022, 30, 100846.	0.4	6
6	Impact of Nitisinone on the Cerebrospinal Fluid Metabolome of a Murine Model of Alkaptonuria. Metabolites, 2022, 12, 477.	1.3	4
7	Assessing bone formation in patients with chronic kidney disease using procollagen type I N-terminal propeptide (PINP): The choice of assay makes a difference. Annals of Clinical Biochemistry, 2021, 58, 528-536.	0.8	8
8	A case report of pregnancy in untreated alkaptonuria â€“ Focus on urinary tissue remodelling markers. Molecular Genetics and Metabolism Reports, 2021, 27, 100766.	0.4	0
9	Alkaptonuria â€“ Many questions answered, further challenges beckon. Annals of Clinical Biochemistry, 2020, 57, 106-120.	0.8	21
10	Homogentisic acid is not only eliminated by glomerular filtration and tubular secretion but also produced in the kidney in alkaptonuria. Journal of Inherited Metabolic Disease, 2020, 43, 737-747.	1.7	18
11	Dietary restriction of tyrosine and phenylalanine lowers tyrosinemia associated with nitisinone therapy of alkaptonuria. Journal of Inherited Metabolic Disease, 2020, 43, 259-268.	1.7	21
12	Evaluation of the 25-hydroxy vitamin D assay on a fully automated liquid chromatography mass spectrometry system, the Thermo Scientific Cascadion SM Clinical Analyzer with the Cascadion 25-hydroxy vitamin D assay in a routine clinical laboratory. Clinical Chemistry and Laboratory Medicine, 2020, 58, 1010-1017.	1.4	21
13	Reversal of ochronotic pigmentation in alkaptonuria following nitisinone therapy: Analysis of data from the United Kingdom National Alkaptonuria Centre. JIMD Reports, 2020, 55, 75-87.	0.7	13
14	The nutritional status of people with alkaptonuria: An exploratory analysis suggests a protein/energy dilemma. JIMD Reports, 2020, 53, 45-60.	0.7	14
15	Nitisinone causes acquired tyrosinosis in alkaptonuria. Journal of Inherited Metabolic Disease, 2020, 43, 1014-1023.	1.7	20
16	Efficacy and safety of once-daily nitisinone for patients with alkaptonuria (SONIA 2): an international, multicentre, open-label, randomised controlled trial. Lancet Diabetes and Endocrinology,the, 2020, 8, 762-772.	5.5	78
17	Evaluation of the serum metabolome of patients with alkaptonuria before and after two years of treatment with nitisinone using LCâ€QTOFâ€MS. JIMD Reports, 2019, 48, 67-74.	0.7	11
18	Quantification of the flux of tyrosine pathway metabolites during nitisinone treatment of Alkaptonuria. Scientific Reports, 2019, 9, 10024.	1.6	16

#	Article	IF	Citations
19	Conditional targeting in mice reveals that hepatic homogentisate 1,2-dioxygenase activity is essential in reducing circulating homogentisic acid and for effective therapy in the genetic disease alkaptonuria. Human Molecular Genetics, 2019, 28, 3928-3939.	1.4	16
20	Interference of hydroxyphenylpyruvic acid, hydroxyphenyllactic acid and tyrosine on routine serum and urine clinical chemistry assays; implications for biochemical monitoring of patients with alkaptonuria treated with nitisinone. Clinical Biochemistry, 2019, 71, 24-30.	0.8	2
21	Assessing the effect of nitisinone induced hypertyrosinaemia on monoamine neurotransmitters in brain tissue from a murine model of alkaptonuria using mass spectrometry imaging. Metabolomics, 2019, 15, 68.	1.4	20
22	A Comprehensive LC-QTOF-MS Metabolic Phenotyping Strategy: Application to Alkaptonuria. Clinical Chemistry, 2019, 65, 530-539.	1.5	17
23	Subclinical ochronosis features in alkaptonuria: a cross-sectional study. BMJ Innovations, 2019, 5, 82-91.	1.0	15
24	Liquid chromatography tandem mass spectrometry: challenges in introducing published methods into the clinical laboratory. Annals of Clinical Biochemistry, 2018, 55, 404-405.	0.8	1
25	Evaluation of the Mitra microsampling device for use with key urinary metabolites in patients with Alkaptonuria. Bioanalysis, 2018, 10, 1919-1932.	0.6	17
26	Data on items of AKUSSI in Alkaptonuria collected over three years from the United Kingdom National Alkaptonuria Centre and the impact of nitisinone. Data in Brief, 2018, 20, 1620-1628.	0.5	10
27	Nitisinone arrests ochronosis and decreases rate of progression of Alkaptonuria: Evaluation of the effect of nitisinone in the United Kingdom National Alkaptonuria Centre. Molecular Genetics and Metabolism, 2018, 125, 127-134.	0.5	89
28	Clinical and biochemical assessment of depressive symptoms in patients with Alkaptonuria before and after two years of treatment with nitisinone. Molecular Genetics and Metabolism, 2018, 125, 135-143.	0.5	15
29	Serum Amino Acid Profiling in Patients with Alkaptonuria Before and After Treatment with Nitisinone. JIMD Reports, 2018, 41, 109-117.	0.7	13
30	The effect of nitisinone on homogentisic acid and tyrosine: a two-year survey of patients attending the National Alkaptonuria Centre, Liverpool. Annals of Clinical Biochemistry, 2017, 54, 323-330.	0.8	39
31	Development of a liquid chromatography tandem mass spectrometry method for the simultaneous measurement of voriconazole, posaconazole and itraconazole. Annals of Clinical Biochemistry, 2017, 54, 686-695.	0.8	10
32	Assessment of the Effect of Once Daily Nitisinone Therapy on 24-h Urinary Metadrenalines and 5-Hydroxyindole Acetic Acid Excretion in Patients with Alkaptonuria After 4ÂWeeks of Treatment. JIMD Reports, 2017, 41, 1-10.	0.7	16
33	Asymptomatic Corneal Keratopathy Secondary to Hypertyrosinaemia Following Low Dose Nitisinone and a Literature Review of Tyrosine Keratopathy in Alkaptonuria. JIMD Reports, 2017, 40, 31-37.	0.7	26
34	Suitability Of Nitisinone In Alkaptonuria 1 (SONIA 1): an international, multicentre, randomised, open-label, no-treatment controlled, parallel-group, dose-response study to investigate the effect of once daily nitisinone on 24-h urinary homogentisic acid excretion in patients with alkaptonuria after 4â€...weeks of treatment. Annals of the Rheumatic Diseases, 2016, 75, 362-367.	0.5	123
35	The impact of calcium assay change on a local adjusted calcium equation. Annals of Clinical Biochemistry, 2016, 53, 292-294.	0.8	4
36	Acute fatal metabolic complications in alkaptonuria. Journal of Inherited Metabolic Disease, 2016, 39, 203-210.	1.7	23

#	Article	IF	Citations
37	Serum markers in alkaptonuria: simultaneous analysis of homogentisic acid, tyrosine and nitisinone by liquid chromatography tandem mass spectrometry. Annals of Clinical Biochemistry, 2015, 52, 597-605.	0.8	46
38	Serum concentrations and urinary excretion of homogentisic acid and tyrosine in normal subjects. Clinical Chemistry and Laboratory Medicine, 2015, 53, e81-3.	1.4	21
39	The Pigment in Alkaptonuria Relationship to Melanin and Other Coloured Substances: A Review of Metabolism, Composition and Chemical Analysis. JIMD Reports, 2015, 24, 51-66.	0.7	32
40	Relationship Between Serum Concentrations of Nitisinone and Its Effect on Homogentisic Acid and Tyrosine in Patients with Alkaptonuria. JIMD Reports, 2015, 24, 21-27.	0.7	26
41	Investigating the Robustness and Diagnostic Potential of Extracellular Matrix Remodelling Biomarkers in Alkaptonuria. JIMD Reports, 2015, 24, 29-37.	0.7	15
42	Analysis of HGD Gene Mutations in Patients with Alkaptonuria from the United Kingdom: Identification of Novel Mutations. JIMD Reports, 2014, 24, 3-11.	0.7	42
43	Urine homogentisic acid and tyrosine: Simultaneous analysis by liquid chromatography tandem mass spectrometry. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2014, 963, 106-112.	1.2	54
44	Vitamin D Assays: Past and Present Debates, Difficulties, and Developments. Calcified Tissue International, 2013, 92, 118-127.	1.5	131
45	Potential problems with using deuterated internal standards for liquid chromatography-tandem mass spectrometry. Annals of Clinical Biochemistry, 2013, 50, 274-274.	0.8	22
46	The Consequences of Valproate Overdose. Clinical Chemistry, 2011, 57, 1233-1237.	1.5	14
47	Adsorption and interactions of dentine phosphoprotein with hydroxyapatite and collagen. European Journal of Oral Sciences, 2006, 114, 223-231.	0.7	33
48	Modulation of Collagen Fibrillogenesis by Dentinal Proteoglycans. Calcified Tissue International, 2005, 76, 127-135.	1.5	38
49	Dentinal Proteoglycans Demonstrate an Increasing Order of Affinity for Hydroxyapatite Crystals During the Transition of Predentine to Dentine. Calcified Tissue International, 2004, 75, 197-204.	1.5	17
50	Odontoblast transport of sulphateâ€"the in vitro influence of fluoride. Archives of Oral Biology, 2003, 48, 377-387.	0.8	4
51	Molecular Interaction of Recombinant Decorin and Biglycan with Type I Collagen Influences Crystal Growth. Connective Tissue Research, 2003, 44, 189-195.	1.1	47
52	Fluoride alters casein kinase II and alkaline phosphatase activity in vitro with potential implications for dentine mineralization. Archives of Oral Biology, 2001, 46, 343-351.	0.8	22
53	The Isolation and Detection of Non-Collagenous Proteins from the Compact Bone of the Dinosaurlguanodon. Connective Tissue Research, 2000, 41, 249-259.	1.1	7
54	Altered Phosphorylation of Rat Dentine Phosphoproteins by Fluoride In Vivo. Calcified Tissue International, 1999, 64, 234-238.	1.5	22

#	Article	IF	Citations
55	Method development and validation for analysis of phenylalanine, 4â€hydroxyphenyllactic acid and 4â€hydroxyphenylpyruvic acid in serum and urine. JIMD Reports, 0, , .	0.7	6